| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Personalized Medicine Market
Personalized Medicine Market 
Companion Diagnostics to Foster the Transformational Trend Towards Personalized Medicine
Hyderabad,
AP,
India
(prbd.net)
23/11/2010
Companion diagnostics facilitate identification of a patient's response to drugs depending on an individual’s genetic or proteomic profile. Companion diagnostics thus allow customization of treatment based on a patient's molecular or genetic make up, minimizing the risk of adverse reactions. Examples of successful therapeutics linked to companion diagnostic tests include Herceptin (trastuzumab), Gleevec (imatinib), Coumadin (warfarin), Camptosar (irinotecan) and Erbitux (cetuximab). Herceptin, for instance, is used to treat breast cancer patients that over-express HER2 protein. This subset of the patient population accounts for nearly 30% of the total breast cancer patients. HercepTest, the first test to be associated with a drug, was launched in 1998. HercepTest detects the over-expression of the HER2 protein, as a result increasing the accuracy and efficacy of treatment. Herceptin generated revenues of $5.2 billion in 2009, a growth of 10% from sales of $4.7 billion in 2007.
For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Personalized-Medicine-Market-Advances-in-Human-Genomics-and-Proteomics-to-Challenge-Traditional-Therapeutics&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
More and more companies are becoming increasingly involved in the development of companion diagnostics owing to the cost-effectiveness and accuracy of companion diagnostics in treatment and the drug discovery process as well. Oncology, in particular, is witnessing increased acceptance of companion diagnostics as the conventional trial and error method can prove to be cumbersome in patients with standard care. Companion diagnostics is also referred to as theranostics, holds immense potential, raising the prospect of a new standard of healthcare.
Developing a new drug is a costly and time-consuming process. The application of advanced technologies for the development of personalized medicine, be it diagnostics or therapeutics, in the drug discovery process is becoming increasingly evident. The integration of pharmacogenomic data in clinical trials and drug development process helps in selecting patients that are more likely to respond or least likely to suffer any side effects. This considerably reduces the time, size and expense of clinical trials and also helps pharmaceutical companies to overcome the challenges posed by conventional processes which are time consuming and expensive.
GBI Research's new report “Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics” provides an in-depth analysis on the potential applications of personalized medicine in pharmaceutical drug discovery and clinical services. The report suggests investment decisions in personalized medicine by providing information on valid personalized therapeutics, biomarkers, companion diagnostics, pipeline, the competitive landscape, mergers and acquisitions and market potential. In addition to this, the report also covers market drivers and restraints for the global personalized medicine market.
For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Personalized-Medicine-Market-Advances-in-Human-Genomics-and-Proteomics-to-Challenge-Traditional-Therapeutics&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|